Remaining pipeline and cash cushion investor blow as Targacept ends another programme
This article was originally published in Scrip
Executive Summary
After Targacept announced the unsuccessful end of its third clinical development programme this year and said for the second time in 2012 that it would lay off employees, the company - which is focused on therapeutics that selectively target neuronal nicotinic receptors (NNRs) to treat nervous system diseases and disorders - experienced a relatively small 11.1% decline in its stock price on 17 September, given its recent string of failures.